Nuclear expression of lysyl oxidase enzyme is an independent prognostic factor in rectal cancer patients

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Nuclear expression of lysyl oxidase enzyme is an independent prognostic factor in rectal cancer patients. / Liu, Na; Cox, Thomas R; Cui, Weiyingqi; Adell, Gunnar; Holmlund, Birgitta; Ping, Jie; Jarlsfelt, Ingvar; Erler, Janine T; Sun, Xiao-Feng.

In: OncoTarget, Vol. 8, No. 36, 01.09.2017, p. 60015-60024.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Liu, N, Cox, TR, Cui, W, Adell, G, Holmlund, B, Ping, J, Jarlsfelt, I, Erler, JT & Sun, X-F 2017, 'Nuclear expression of lysyl oxidase enzyme is an independent prognostic factor in rectal cancer patients', OncoTarget, vol. 8, no. 36, pp. 60015-60024. https://doi.org/10.18632/oncotarget.9623

APA

Liu, N., Cox, T. R., Cui, W., Adell, G., Holmlund, B., Ping, J., Jarlsfelt, I., Erler, J. T., & Sun, X-F. (2017). Nuclear expression of lysyl oxidase enzyme is an independent prognostic factor in rectal cancer patients. OncoTarget, 8(36), 60015-60024. https://doi.org/10.18632/oncotarget.9623

Vancouver

Liu N, Cox TR, Cui W, Adell G, Holmlund B, Ping J et al. Nuclear expression of lysyl oxidase enzyme is an independent prognostic factor in rectal cancer patients. OncoTarget. 2017 Sep 1;8(36):60015-60024. https://doi.org/10.18632/oncotarget.9623

Author

Liu, Na ; Cox, Thomas R ; Cui, Weiyingqi ; Adell, Gunnar ; Holmlund, Birgitta ; Ping, Jie ; Jarlsfelt, Ingvar ; Erler, Janine T ; Sun, Xiao-Feng. / Nuclear expression of lysyl oxidase enzyme is an independent prognostic factor in rectal cancer patients. In: OncoTarget. 2017 ; Vol. 8, No. 36. pp. 60015-60024.

Bibtex

@article{573b4a7d7479401a90a3e0953c4a8b94,
title = "Nuclear expression of lysyl oxidase enzyme is an independent prognostic factor in rectal cancer patients",
abstract = "Emerging evidence has implicated a pivotal role for lysyl oxidase (LOX) in cancer progression and metastasis. Whilst the majority of work has focused on the extracellular matrix cross-linking role of LOX, the exact function of intracellular LOX localisation remains unclear. In this study, we analysed the LOX expression patterns in the nuclei of rectal cancer patient samples and determined the clinical significance of this expression. Nuclear LOX expression was significantly increased in patient lymph node metastases compared to their primary tumours. High nuclear LOX expression in tumours was correlated with a high rate of distant metastasis and increased recurrence. Multivariable analysis showed that high nuclear LOX expression was also correlated with poor overall survival and disease free survival. Furthermore, we are the first to identify LOX enzyme isoforms (50 kDa and 32 kDa) within the nucleus of colon cancer cell lines by confocal microscopy and Western blot. Our results show a powerful link between nuclear LOX expression in tumours and patient survival, and offer a promising prognostic biomarker for rectal cancer patients.",
author = "Na Liu and Cox, {Thomas R} and Weiyingqi Cui and Gunnar Adell and Birgitta Holmlund and Jie Ping and Ingvar Jarlsfelt and Erler, {Janine T} and Xiao-Feng Sun",
year = "2017",
month = sep,
day = "1",
doi = "10.18632/oncotarget.9623",
language = "English",
volume = "8",
pages = "60015--60024",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "36",

}

RIS

TY - JOUR

T1 - Nuclear expression of lysyl oxidase enzyme is an independent prognostic factor in rectal cancer patients

AU - Liu, Na

AU - Cox, Thomas R

AU - Cui, Weiyingqi

AU - Adell, Gunnar

AU - Holmlund, Birgitta

AU - Ping, Jie

AU - Jarlsfelt, Ingvar

AU - Erler, Janine T

AU - Sun, Xiao-Feng

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Emerging evidence has implicated a pivotal role for lysyl oxidase (LOX) in cancer progression and metastasis. Whilst the majority of work has focused on the extracellular matrix cross-linking role of LOX, the exact function of intracellular LOX localisation remains unclear. In this study, we analysed the LOX expression patterns in the nuclei of rectal cancer patient samples and determined the clinical significance of this expression. Nuclear LOX expression was significantly increased in patient lymph node metastases compared to their primary tumours. High nuclear LOX expression in tumours was correlated with a high rate of distant metastasis and increased recurrence. Multivariable analysis showed that high nuclear LOX expression was also correlated with poor overall survival and disease free survival. Furthermore, we are the first to identify LOX enzyme isoforms (50 kDa and 32 kDa) within the nucleus of colon cancer cell lines by confocal microscopy and Western blot. Our results show a powerful link between nuclear LOX expression in tumours and patient survival, and offer a promising prognostic biomarker for rectal cancer patients.

AB - Emerging evidence has implicated a pivotal role for lysyl oxidase (LOX) in cancer progression and metastasis. Whilst the majority of work has focused on the extracellular matrix cross-linking role of LOX, the exact function of intracellular LOX localisation remains unclear. In this study, we analysed the LOX expression patterns in the nuclei of rectal cancer patient samples and determined the clinical significance of this expression. Nuclear LOX expression was significantly increased in patient lymph node metastases compared to their primary tumours. High nuclear LOX expression in tumours was correlated with a high rate of distant metastasis and increased recurrence. Multivariable analysis showed that high nuclear LOX expression was also correlated with poor overall survival and disease free survival. Furthermore, we are the first to identify LOX enzyme isoforms (50 kDa and 32 kDa) within the nucleus of colon cancer cell lines by confocal microscopy and Western blot. Our results show a powerful link between nuclear LOX expression in tumours and patient survival, and offer a promising prognostic biomarker for rectal cancer patients.

U2 - 10.18632/oncotarget.9623

DO - 10.18632/oncotarget.9623

M3 - Journal article

C2 - 28947950

VL - 8

SP - 60015

EP - 60024

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 36

ER -

ID: 165803467